The latest issue of EMJ Oncology is out now featuring engaging content, including a review article examining colorectal cancer during pregnancy and an analysis of optimal immunohistochemical cut-off markers in breast cancer. The journal also showcases an insightful review of the European Society for Medical Oncology (ESMO) Congress 2022, highlighting late-breaking abstracts presented there.
Latest articlesAll articles
EGFR-Mutant Non-small Cell Lung Cancer: State-of-the-Art and Future Perspectives
Epidermal growth factor receptors (EGFR), the first of four members of the ErbB family, play essential roles in both normal physiological and cancerous conditions. EGFR is characterised by an extracellular ligand-binding domain, which when activated by the ligand leads to the receptor dimerisation; a transmembrane domain, responsible for the dimerisation; and an intracellular tyrosine kinase domain that activates the intracellular kinase domain and the autophosphorylation of tyrosine residues within the cytoplasmic domain of the receptor.
Infographic: ESMO Recommendations for Diagnosis and Staging of Metastatic Non-Small-Cell Lung Cancer
ESMO Recommendations for Diagnosis and Staging of Metastatic Non-Small-Cell Lung Cancer. Bronchoscopy: for central lesions; can be paired with bronchial washing, brushing, and bronchial and transbronchial biopsy
Novel Biomarkers and Drug Targets in Non-Small Cell Lung Cancer
Despite therapeutic advances, the prognosis of non-small cell lung cancers (NSCLC) is still very poor, especially when first diagnosed at later stages involving metastases. NSCLC classification can be aided by identifying genetic, molecular, and histological subtypes that are important biomarkers in treatment selection. The majority of targeted therapies are now first-line treatment options for eligible patients with advanced stages of NSCLC.
Neratinib as a Potential Therapeutic for Mutant RAS and Osimertinib-Resistant Tumours
Neratinib was developed as an irreversible catalytic inhibitor of ERBB2, which also acts to inhibit ERBB1 and ERBB4. Neratinib is U.S. Food and Drug Administration (FDA)-approved as a neo-adjuvant therapy for use in HER2+ breast cancer.